Published in Am J Pathol on December 01, 2003
Ebola haemorrhagic fever. Lancet (2011) 8.28
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol (2006) 4.01
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A (2012) 3.35
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis (2010) 2.24
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
What factors might have led to the emergence of Ebola in West Africa? PLoS Negl Trop Dis (2015) 2.07
Disease modeling for Ebola and Marburg viruses. Dis Model Mech (2009) 2.07
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.92
Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res (2009) 1.91
The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83
Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog (2009) 1.78
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol (2008) 1.78
Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis (2011) 1.75
Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol (2008) 1.65
Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol (2009) 1.62
Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62
Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol (2005) 1.61
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol (2006) 1.58
Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57
TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog (2013) 1.53
A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis (2012) 1.51
Animal models for Ebola and Marburg virus infections. Front Microbiol (2013) 1.51
Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol (2005) 1.47
Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med (2004) 1.44
Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013-2016 Epidemic. Cell (2016) 1.35
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32
Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain. Emerg Infect Dis (2015) 1.31
Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J (2007) 1.30
Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol (2010) 1.29
Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis (2012) 1.27
Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother (2009) 1.26
T cell-dependence of Lassa fever pathogenesis. PLoS Pathog (2010) 1.25
The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology (2011) 1.22
The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol (2007) 1.20
Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology (2007) 1.19
IAP-IAP complexes required for apoptosis resistance of C. trachomatis-infected cells. PLoS Pathog (2006) 1.17
Pathogenesis of Lassa fever in cynomolgus macaques. Virol J (2011) 1.16
Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol (2009) 1.16
Virological and serological findings in Rousettus aegyptiacus experimentally inoculated with vero cells-adapted hogan strain of Marburg virus. PLoS One (2012) 1.15
Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol (2011) 1.14
Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J Virol (2014) 1.14
Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein. Virology (2008) 1.14
An upstream open reading frame modulates ebola virus polymerase translation and virus replication. PLoS Pathog (2013) 1.12
Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys. Blood (2005) 1.11
T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome. J Virol (2011) 1.10
Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells. J Infect Dis (2011) 1.09
The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J Virol (2006) 1.09
Bluetongue virus targets conventional dendritic cells in skin lymph. J Virol (2009) 1.08
Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol (2015) 1.07
Mouse models for filovirus infections. Viruses (2012) 1.07
Effect of SIVmac infection on plasmacytoid and CD1c+ myeloid dendritic cells in cynomolgus macaques. Immunology (2008) 1.06
Gastrointestinal and Hepatic Manifestations of Ebola Virus Infection. Dig Dis Sci (2015) 1.06
Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola viruses. J Virol (2006) 1.05
Thrombocytopenia in Dengue: Interrelationship between Virus and the Imbalance between Coagulation and Fibrinolysis and Inflammatory Mediators. Mediators Inflamm (2015) 1.05
Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antiviral Res (2010) 1.04
Filovirus entry: a novelty in the viral fusion world. Viruses (2012) 1.03
A small nonhuman primate model for filovirus-induced disease. Virology (2011) 1.03
Ebolavirus vaccines for humans and apes. Curr Opin Virol (2012) 1.01
Ebola virus transmission in guinea pigs. J Virol (2014) 1.01
Intracellular events and cell fate in filovirus infection. Viruses (2011) 1.01
Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ (2015) 1.00
Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J Virol (2007) 1.00
GB virus C coinfections in west African Ebola patients. J Virol (2014) 0.99
The multiple roles of sGP in Ebola pathogenesis. Viral Immunol (2015) 0.98
Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques. J Virol (2015) 0.94
Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res (2014) 0.94
Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty (2014) 0.94
Phosphatidylserine receptors: enhancers of enveloped virus entry and infection. Virology (2014) 0.93
Ebolavirus VP35 interacts with the cytoplasmic dynein light chain 8. J Virol (2009) 0.93
Ebola virus entry: a curious and complex series of events. PLoS Pathog (2015) 0.93
The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J Gen Virol (2009) 0.92
The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res (2012) 0.92
Advances in virus-like particle vaccines for filoviruses. J Infect Dis (2011) 0.92
Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis (2011) 0.92
Ebola: a holistic approach is required to achieve effective management and control. J Allergy Clin Immunol (2015) 0.92
Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus. PLoS Negl Trop Dis (2014) 0.91
A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species- and cell-type-specific manner. J Virol (2013) 0.91
An animal model that reflects human disease: the common marmoset (Callithrix jacchus). Curr Opin Virol (2012) 0.91
Correlates of immunity to filovirus infection. Viruses (2011) 0.91
Host cell factors in filovirus entry: novel players, new insights. Viruses (2012) 0.91
Crimean-Congo hemorrhagic fever virus-infected hepatocytes induce ER-stress and apoptosis crosstalk. PLoS One (2012) 0.91
Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells. J Virol (2015) 0.90
Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection. J Virol (2011) 0.89
Basolateral entry and release of Crimean-Congo hemorrhagic fever virus in polarized MDCK-1 cells. J Virol (2006) 0.89
Differential requirements for clathrin endocytic pathway components in cellular entry by Ebola and Marburg glycoprotein pseudovirions. Virology (2011) 0.89
Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses. Proc Natl Acad Sci U S A (2015) 0.87
Interferon-Induced Transmembrane Protein-Mediated Inhibition of Host Cell Entry of Ebolaviruses. J Infect Dis (2015) 0.86
Dendritic cells in viral pathogenesis: protective or defective? Int J Exp Pathol (2005) 0.86
Immunobiology of dendritic cells. Annu Rev Immunol (2000) 23.65
Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol (1995) 9.35
Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet (1977) 9.23
Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 8.32
The acute phase response. Immunol Today (1994) 7.53
The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis (1999) 7.39
The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A (1996) 7.02
Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity (1997) 6.15
Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med (1999) 5.85
Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med (1990) 5.35
Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent. Lancet (1977) 5.32
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis (1998) 4.50
Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med (1990) 4.48
Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res (1993) 3.89
Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med (1999) 3.64
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis (1999) 3.62
TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med (1997) 3.59
Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J Exp Med (2000) 3.50
Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis (1999) 3.47
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol (2002) 2.93
Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med (1997) 2.90
Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis (1999) 2.76
Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med (1999) 2.76
Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl (1996) 2.69
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol (1995) 2.56
Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest (2000) 2.45
Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol (2001) 2.39
Differentiation of filoviruses by electron microscopy. Virus Res (1995) 2.39
Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis (2002) 2.26
Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol (1996) 2.26
Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity (2001) 2.24
Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J Virol (2000) 2.24
Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med (1996) 2.23
Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells. J Exp Med (1997) 2.21
Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med (1999) 2.13
Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06
Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis (1985) 2.02
Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol (2001) 1.94
Infection and activation of monocytes by Marburg and Ebola viruses. J Virol (2001) 1.90
Ebola haemorrhagic fever: experimental infection of monkeys. Trans R Soc Trop Med Hyg (1978) 1.88
Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression. Proc Natl Acad Sci U S A (1997) 1.85
Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis (1992) 1.84
Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis (1999) 1.83
Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol (1999) 1.83
TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol (1998) 1.81
Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol (1992) 1.78
Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother (1996) 1.73
An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis (1999) 1.67
Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch Pathol Lab Med (1997) 1.61
Enhanced virus resistance of transgenic mice expressing the human MxA protein. J Virol (1995) 1.56
Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch Virol (1996) 1.53
Measles virus induces functional TRAIL production by human dendritic cells. J Virol (2000) 1.43
Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents (1999) 1.36
Immunomodulating effects of antibiotics: literature review. Infection (1997) 1.35
Antigen-presentation by macrophages but not by dendritic cells in human immunodeficiency virus (HIV) infection. Immunology (1992) 1.30
Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis (2000) 1.25
[The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever]. Vopr Virusol (1994) 1.24
[Development and study of the properties of immunoglobulin against Ebola fever]. Vopr Virusol (1996) 1.19
Apoptosis: molecular aspects of cell death and disease. Lab Invest (1998) 1.11
Dendritic cells: a major story unfolds. Immunol Today (1995) 1.06
Direct evidence that interferon-beta mediates enhanced HLA-class I expression in measles virus-infected cells. J Immunol (1993) 1.04
[Developing principles for emergency prevention and treatment of Ebola fever]. Vopr Virusol (1997) 1.03
Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. J Immunol (1995) 1.00
[Attempts to develop a vaccine against Ebola fever]. Vopr Virusol (1996) 1.00
Alterations in intestinal bacterial flora modulate the systemic cytokine response to hemorrhagic shock. Am J Physiol (1995) 0.99
Adenovirus L4-100K assembly protein is a granzyme B substrate that potently inhibits granzyme B-mediated cell death. Immunity (2001) 0.98
[Experimental Ebola fever in Macaca mulatta]. Vopr Virusol (1995) 0.93
Characterization of the cytotoxic factor(s) released from thymic dendritic cells upon human immunodeficiency virus type 1 infection. Virology (1998) 0.93
Influence of gut microflora on mesenteric lymph cytokine production in rats with hemorrhagic shock. J Trauma (2002) 0.93
The GP-protein of Marburg virus contains the region similar to the 'immunosuppressive domain' of oncogenic retrovirus P15E proteins. FEBS Lett (1993) 0.92
Human large granular lymphocytes and natural killing ultrastructural studies of strontium-induced degranulation. Eur J Immunol (1982) 0.92
Ebola virus glycoprotein demonstrates differential cellular localization in infected cell types of nonhuman primates and guinea pigs. Arch Pathol Lab Med (2001) 0.88
Accessory cells in normal human and rodent lymph nodes: morphology, phenotype, and functional implications. Curr Top Pathol (1990) 0.87
Nitric oxide induces a decrease in the mitochondrial membrane potential of peripheral blood lymphocytes, especially in natural killer cells. Antioxid Redox Signal (2000) 0.87
[Effects of antibiotics on production of cytokines by human monocytes]. Pathol Biol (Paris) (1993) 0.85
Mononuclear phagocytic and dendritic cell systems. J Am Acad Dermatol (1990) 0.80
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Exotic emerging viral diseases: progress and challenges. Nat Med (2004) 4.54
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest (2003) 3.57
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio (2014) 3.49
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci U S A (2004) 2.98
Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg (2010) 2.92
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med (2015) 2.71
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature (2011) 2.36
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A (2004) 2.36
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis (2002) 2.26
Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 2.24
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med (2007) 2.23
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis (2007) 2.09
Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol (2011) 1.99
Growth factor independent-1 induced by IL-4 regulates Th2 cell proliferation. Immunity (2002) 1.99
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med (2013) 1.98
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity. Infect Immun (2004) 1.95
BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem (2004) 1.92
The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81